However, it is reported that bevacizumab from tumour‐derived EVs could not bind to VEGFA, so there is a possibility that tumour cells escape themselves from treatment by bevacizumab shedding at the surface of tumour‐derived EVs.86 This evidence concerns the gene VEGFA and neoplasm.